TipRanks Cyber Monday Sale
- Claim 60% off TipRanks Premium for data-backed insights and research tools you need to invest with confidence.
- Subscribe to TipRanks' Smart Investor Picks and see our data in action through our high-performing model portfolio - now also 60% off
HBM Holdings Ltd. ( (HK:2142) ) has provided an announcement.
HBM Holdings Ltd. has announced that its first-in-human Phase 1 clinical study design for MesoC2, a mesothelin-targeting ADC, will be presented at the 2025 ASCO Annual Meeting by its collaborator, Pfizer. MesoC2, developed using HBM’s proprietary platforms, is being tested for safety and efficacy in patients with advanced solid tumors, potentially positioning it as a globally best-in-class therapeutic option.
More about HBM Holdings Ltd.
HBM Holdings Ltd. is a biotechnology company involved in the development of innovative therapeutic solutions, focusing on antibody-drug conjugates (ADCs) for cancer treatment. The company operates through its subsidiaries, including Nona Biosciences, and collaborates with global partners like Pfizer to advance its research and development efforts.
Average Trading Volume: 11,372,488
Technical Sentiment Signal: Buy
Current Market Cap: HK$8.19B
For an in-depth examination of 2142 stock, go to TipRanks’ Stock Analysis page.